More importantly, the strategy of targeting YAP1 to drive CAF phenotype switching from pro-tumor to anti-tumor offers a highly attractive new avenue for overcoming the immunosuppressive TME in PCa and improving immunotherapy response. The gene discussed is YAP1; the disease is posterior cortical atrophy.